Accepted abstracts showcase Nexalin’s proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinical improvements across anxiety, depression, insomnia and quality of life Data to be presented include 77.8% anxiety response rate at end of treatment, durable benefits maintained at 8-week follow-up and no serious adverse events, seizures or manic/hypomanic switches reported Presentations of clinical data further strengthen the scientific viability of Nexalin’s new proprietary non-invasive approach to deep-brain frequency-based neurostimulation as the Company prepares for global commercial initiatives HOUSTON, TX, June 16, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that two clinical abstracts evaluating Nexalin’s proprietary DIFS™ 15 mA, 77.5 Hz treatment platform have been accepted for presentation at the 2026 NYC Neuromodulation Conference. The accepted abstracts are titled: “Transcranial Alternating Current Stimulation for the Treatment of Anxiety: Preliminary Results from an Open-Label Pilot Clinical Trial” “Transcranial Alternating Current Stimulation for Comorbid Anxiety and Insomnia: Preliminary Findings on Insomnia and Quality of Life from an Open-Label Pilot Trial” The accepted abstracts are based on data from the Company’s recently completed 8-week, single-center, prospective, clinical trial conducted at the Institute of Psychiatry, Hospital das Clínicas, University of São Paulo. Adults with generalized anxiety disorder and comorbid insomnia received 20 sessions of Nexalin’s proprietary 15 mAmp deep-brain frequency stimulation over four weeks, followed by a four-week follow-up period. Each 40-minute session was administered using the Nexalin DIFS™ device at 15 mA and 77.5 Hz. “The acceptance of two Nexalin-related clinical abstracts for presentation at the 2026 NYC Neuromodulation Conference is another important milestone for our proprietary non-invasive treatment platform,” said Mark White, Chief Executive Officer of Nexalin Technology. “These presentations will showcase Nexalin’s clinical results to a highly relevant scientific and medical audience, while underscoring what we believe may represent a distinction between Nexalin and all other competitors in the field: Nexalin is not advancing a conventional or “me-too” neurostimulation device, but a potentially differentiated, next-generation neuro-technology platform designed to set a new standard for non-invasive brain stimulation." Mr. White continued, “We believe these accepted abstracts reinforce the growing clinical and scientific foundation behind Nexalin’s DIFS™ platform. The data continue to affirm the positive clinical signals observed in prior Nexalin studies and highlight meaningful improvements across multiple interconnected neuropsychiatric domains, including anxiety, depressive symptoms, insomnia and quality of life. As we advance broader clinical, regulatory and commercial initiatives, we believe this additional scientific visibility is highly valuable, including in Brazil, where the study was conducted and where we are preparing for a potential product launch.” Key highlights from the accepted abstracts include: 77.8% anxiety response rate at end of treatment: Anxiety response rates reached 77.8% at Session 20. Rapid anxiety improvement: Hamilton Anxiety Rating Scale (HAM-A) scores decreased by 14.73 points by Session 5. Durable anxiety benefit: HAM-A scores decreased by 18.30 points by Session 20, with reductions observed at 8-week post-treatment follow-up. Depressive symptom improvement: Hamilton Depression Rating Scale (HAMD) scores decreased by 9.90 points by Session 20. High depressive symptom response and remission: HAMD response and remission rates both reached 66.7% at the end of treatment. Sustained insomnia improvement: Pittsburgh Sleep Quality Index (PSQI) scores improved significantly at the end of treatment and remained significantly improved at 8-week follow-up, with large effect sizes reported. Quality-of-life improvement: Overall quality of life improved significantly at the end of treatment, with favorable directional trends across additional quality-of-life domains. Favorable tolerability profile: No serious adverse events, seizures or manic/hypomanic switches were reported. “These accepted abstracts are important because they reflect that Nexalin’s clinical findings are moving into broader scientific discussion within the neuromodulation field,” said Dr. David Owens, Chief Medical Officer of Nexalin Technology. “The data show a consistent pattern of improvement across multiple clinically relevant outcomes, not just a single endpoint. Moreover, they provide a strong rationale for continued evaluation of Nexalin’s platform and further support the clinical utility demonstrated across the Company’s published and ongoing body of evidence.” The NYC Neuromodulation Con